Christopher Smith Ph.D Overview

  • Primary Position
  • Partner

  • Primary Industry
  • Healthcare

  • Active Board Seats
  • 7

  • Med. Deal Size

  • Med. Valuation

Christopher Smith Ph.D General Information

Biography

Dr. Christopher Smith serves as a Board Member at Aravax. He serves as a Partner at Brandon Capital. He serves as a Board Member at Q-Sera. He also serves as a Board Member at Ena Respiratory & Okogen. He also serves as a Board Member at Innavac. He served as a Board Member at Solvanix. Before this, he was a Business Development Manager with CSL Ltd, Australia's largest pharmaceutical company and one of the top 10 biotechnology companies in the world. At CSL he was responsible for identifying and reviewing opportunities for CSL's global R&D pipeline. As a consequence, he has extensive experience with both in-licensing and out-licensing therapeutic drugs and R&D enabling platforms. He spent three years as a postdoctoral scientist at The University of Cambridge, UK. He has a first-class honours degree in science from the University of Melbourne, a PhD in Immunology conducted at the Walter and Eliza Hall Institute, and an MBA specializing in innovation and entrepreneurship from the University of Cambridge.

Contact Information

Primary Position
Partner, Brandon Capital
Education
University of Cambridge, MBA (Master of Business Administration)
University of Melbourne, BS (Bachelor of Science)
Gender
Male
Email
cs
Phone
+61 (03)
Address
  • Level 9
  • 31 Queen Street
  • Melbourne, Victoria 3000
  • Australia
+61 (03)

Christopher Smith Ph.D Positions (2)

Firm name Firm type Title Location Industry Since
Axelia Oncology Company Chairman Melbourne, Australia Drug Discovery
Brandon Capital Investor Partner Melbourne, Australia Venture Capital

Christopher Smith Ph.D Board Seats (7)

Company Industry Ownership Status Financing Status Location Since
Aravax Drug Discovery Privately Held (backing) Venture Capital-Backed Melbourne, Australia
Axelia Oncology Drug Discovery Privately Held (backing) Venture Capital-Backed Melbourne, Australia
Denteric Drug Discovery Privately Held (backing) Venture Capital-Backed Melbourne, Australia
Ena Respiratory Drug Discovery Privately Held (backing) Venture Capital-Backed Melbourne, Australia
MycRx Drug Discovery Privately Held (backing) Venture Capital-Backed Melbourne, Australia

Christopher Smith Ph.D Lead Partner on Deals (8)

Christopher Smith Ph.D has been the lead partner on 8 deals. Their latest deal was with Q-Sera, a medical supplies company. The deal was made for on 20-Mar-2024.

Company Deal Date Deal Type Deal Size Deal Status Industry Location
Q-Sera 20-Mar-2024 Later Stage VC (Series A2) Completed Medical Supplies Melbourne, Australia
Aravax 23-Jan-2024 Completed Drug Discovery Melbourne, Australia
Aravax 20-Dec-2022 Completed Drug Discovery Melbourne, Australia
Ena Respiratory 15-Jun-2021 Completed Drug Discovery Melbourne, Australia
Aravax 26-Jul-2018 Completed Drug Discovery Melbourne, Australia
Okogen 27-Feb-2018 Completed Drug Discovery Plano, TX
MycRx 23-Mar-2016 Early Stage VC (Series A) Completed Drug Discovery Melbourne, Australia
Solvanix 15-Jan-2015 Early Stage VC Completed Biotechnology Darlinghurst, Australia

Christopher Smith Ph.D Network (68)

Board Members (30)

Name Company Representing Location From
Anne-Laure Puaux Ph.D Denteric Self Melbourne, Australia
Brett Haumann Aravax Self Melbourne, Australia
MycRx Self Melbourne, Australia
MycRx Self Melbourne, Australia
Okogen Self Plano, TX

Portfolio Executives (26)

Name Company Role Deal date Location
Michael Grant Q-Sera Co-Founder & Chief Executive Officer 20-Mar-2024 Melbourne, Australia
Ralph Zitnik MD Aravax Chief Medical Officer 23-Jan-2024 Melbourne, Australia
Aravax Chief Executive Officer 23-Jan-2024 Melbourne, Australia
Aravax Co-Founder 23-Jan-2024 Melbourne, Australia
Aravax Co-Inventor, Co-Founder and Co-Chief Scientific Officer 23-Jan-2024 Melbourne, Australia

Fund Team Members (12)

Name Investor Fund Fund Location
Bob Soh MD Brandon Capital MRCF5 Melbourne, Australia
Stephen Thompson Ph.D Bioscience Managers The Biomedical Translation Fund Melbourne, Australia
Brandon Capital Melbourne, Australia
OneVentures Sydney, Australia
Australian Government (Landing Pads) Canberra, Australia

Christopher Smith Ph.D Affiliated Funds (4)

Fund Investor Fund Type Status Vintage Size Dry Powder IRR IRR Quartile
The Biomedical Translation Fund Bioscience Managers Venture Capital - Later Stage Closed 2017
Medical Research Commercialisation Fund Brandon Capital Venture - General Fully Invested 2007
Medical Research Commercialisation Fund III Brandon Capital Venture - General Closed 2015
MRCF5 Brandon Capital Venture Capital - Early Stage Closed 2019

Christopher Smith Ph.D FAQs

  • Who is Christopher Smith Ph.D?

    Dr. Christopher Smith serves as a Board Member at Aravax.

  • How much does Christopher Smith Ph.D typically invest?

    Christopher Smith Ph.D's median deal size is .

  • What is Christopher Smith Ph.D’s main position?

    Christopher Smith Ph.D’s primary position is Partner.

  • What are the contact details for Christopher Smith Ph.D?

    Christopher Smith Ph.D’s email address is cs and his phone number is +61 (03) .

  • How many active board seats does Christopher Smith Ph.D hold?

    Christopher Smith Ph.D holds 7 board seats including Aravax, Axelia Oncology, Denteric, Ena Respiratory, and MycRx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »